問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Division of Endocrinology

List

45Cases

2012-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Study ended8Sites

2014-04-01 - 2016-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-12-01 - 2015-09-30

Phase III

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Patients with Type 2 Diabetes Mellitus: The ELEMENT 4 Study

  • Condition/Disease

    Type II diabetes

  • Test Drug

    Insulin Basal Analog V (LY2963016)

Participate Sites
9Sites

Terminated9Sites

2019-02-15 - 2021-04-22

Phase III

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2019-04-01 - 2022-12-15

Phase III

A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-3)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2010-03-03 - 2010-12-14

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-07-19 - 2018-06-25

Phase III

PIONEER 6 – Cardiovascular outcomes. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Oral Semaglutide

Participate Sites
4Sites

Terminated4Sites

2009-03-01 - 2011-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-05-01 - 2013-06-30

Phase III

A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245,20 or 1245.23.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

2012-01-01 - 2013-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB